國家衛生研究院 NHRI:Item 3990099045/16289
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12189/12972 (94%)
造访人次 : 973901      在线人数 : 1112
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/16289


    题名: 2024 guidelines of the Taiwan society of cardiology on the primary prevention of atherosclerotic cardiovascular disease --- Part II
    作者: Chao, TH;Lin, TH;Cheng, CI;Wu, YW;Ueng, KC;Wu, YJ;Lin, WW;Leu, HB;Cheng, HM;Huang, CC;Wu, CC;Lin, CF;Chang, WT;Pan, WH;Chen, PR;Ting, KH;Su, CH;Chu, CS;Chien, KL;Yen, HW;Wang, YC;Su, TC;Liu, PY;Chang, HY;Chen, PW;Juang, JJ;Lu, YW;Lin, PL;Wang, CP;Ko, YS;Chiang, CE;Hou, CJ;Wang, TD;Lin, YH;Huang, PH;Chen, WJ
    贡献者: Institute of Cellular and Systems Medicine;Institute of Population Health Sciences
    摘要: For the primary prevention of atherosclerotic cardiovascular disease (ASCVD), the recommended treatment target for each modifiable risk factor is as follows: reducing body weight by 5-10%; blood pressure < 130/80 mmHg (systolic pressure < 120 mmHg in high-risk individuals); low-density lipoprotein cholesterol (LDL-C) < 100 mg/dL in high-risk individuals, LDL-C < 115 mg/dL in moderate-risk individuals, LDL-C < 130 mg/dL in low-risk individuals, and LDL-C < 160 mg/dL in those with a minimal; complete and persistent abstinence from cigarette smoking; hemoglobin A1C < 7.0%; fulfilling recommended amounts of the six food groups according to the Taiwan food guide; and moderate-intensity physical activity 150 min/wk or vigorous physical activity 75 min/wk. For the primary prevention of ASCVD by pharmacological treatment in individuals with modifiable risk factors/clinical conditions, statins are the first-line therapy for reducing LDL-C levels; some specific anti-diabetic drugs proven to be effective in randomized controlled trials for the primary prevention of ASCVD are recommended in patients with type 2 diabetes mellitus; pharmacological treatment is recommended to assist in weight management for obese patients with a body mass index ≥ 30 kg/m(2) (or 27 kg/m(2) who also have at least one ASCVD risk factor or obesity-related comorbidity); an angiotensin-converting enzyme inhibitor, a glucagon-like peptide-1 receptor agonist, a sodium-dependent glucose cotransporter-2 inhibitor, and finerenone can be used in diabetic patients with chronic kidney disease for the primary prevention of ASCVD. Of note, healthcare providers are at full discretion in clinical practice, owing to the diversity of individuals and practice, and the availability of resources and facilities.
    日期: 2024-11
    關聯: Acta Cardiologica Sinica. 2024 Nov;40(6):669-715.
    Link to: http://dx.doi.org/10.6515/acs.202411_40(6).20240724b
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1011-6842&DestApp=IC2JCR
    显示于类别:[吳志成] 期刊論文
    [潘文涵] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB39582845.pdf1200KbAdobe PDF5检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈